Dementia, Executive Function and PSP

Dementia, Executive Function and PSP

Dementia can be a symptom of progressive supranuclear palsy (PSP). PSP is a rare neurodegenerative disease that affects movement, balance, speech, and eye movements. As the disease progresses, it can also affect cognition, behavior, and emotions. While not all individuals with PSP will develop dementia, studies have shown that up to 80% of individuals with PSP may experience some degree of cognitive impairment.

The type of dementia associated with PSP is typically referred to as subcortical dementia, which is characterized by a slowing of mental processing, difficulty with executive function (such as planning, organizing, and problem-solving), and changes in mood and behavior. Unlike other types of dementia, memory loss is not typically a prominent feature of subcortical dementia.

Because PSP is a relatively rare disease, there are limited treatment options available to manage cognitive symptoms. However, some medications that are commonly used to treat other types of dementia, such as acetylcholinesterase inhibitors, may be helpful in managing cognitive symptoms in individuals with PSP. Additionally, supportive care, such as occupational therapy and speech therapy, can help improve overall functioning and quality of life for individuals with PSP and cognitive symptoms.

Executive function refers to a set of cognitive processes that are responsible for planning, organizing, initiating, and monitoring complex behaviors and goal-directed actions. Executive function can be affected in individuals with progressive supranuclear palsy (PSP).

As PSP progresses, it can cause changes in executive function, making it difficult for individuals to plan and organize daily activities, initiate tasks, and multitask. In particular, individuals with PSP may have difficulty with set-shifting, which is the ability to switch between different tasks or mental sets, and inhibitory control, which is the ability to stop an ongoing action or response.

These changes in executive function can significantly impact an individual's ability to function independently and may require adaptations to their daily routines, such as breaking down tasks into smaller steps, using reminders or checklists, and simplifying the environment to reduce distractions.

Occupational therapy and cognitive rehabilitation may also be helpful in improving executive function in individuals with PSP. These interventions typically involve working with a therapist to develop strategies and techniques to manage specific challenges related to executive function, such as planning and organizing, time management, and memory.

Back to blog

Leave a public comment:

Please note, comments need to be approved before they are published.

  • 🥯 Bagel Fundraiser

    🥯 Bagel Fundraiser

    JOIN THE COLEEN CUNNINGHAM FOUNDATION 🥯 Bagel Fundraiser FOR THE BENEFIT OF THOSE WITHAtypical Parkinson Diseases NOVEMBER 2ND • 11-1 PM AT THE ROCKVILLE JCC IN PARTNERSHIP WITH BETHESDA BAGELS

    🥯 Bagel Fundraiser

    JOIN THE COLEEN CUNNINGHAM FOUNDATION 🥯 Bagel Fundraiser FOR THE BENEFIT OF THOSE WITHAtypical Parkinson Diseases NOVEMBER 2ND • 11-1 PM AT THE ROCKVILLE JCC IN PARTNERSHIP WITH BETHESDA BAGELS

  • HOPE by Bhavna

    HOPE by Bhavna

    Remember the first timerobins sang in your garden,their delicate bodies pulsing with song,their hearts daring to rise, like yours.How the moon spilled its silver over your window,and your mother said,...

    HOPE by Bhavna

    Remember the first timerobins sang in your garden,their delicate bodies pulsing with song,their hearts daring to rise, like yours.How the moon spilled its silver over your window,and your mother said,...

  • Active Neurodegenerative Disease Clinical Trials (PSP, MSA, DLB, CBS, Parkinsonian Syndromes)

    Active Neurodegenerative Disease Clinical Trial...

    Progressive Supranuclear Palsy (PSP) Trials ClinicalTrials.gov ID: NCT06355531 – PROSPERPurpose: To evaluate whether FNP-223 slows disease progression in PSP, using the PSP Rating Scale (PSPRS) over 52 weeks. The trial also...

    1 comment

    Active Neurodegenerative Disease Clinical Trial...

    Progressive Supranuclear Palsy (PSP) Trials ClinicalTrials.gov ID: NCT06355531 – PROSPERPurpose: To evaluate whether FNP-223 slows disease progression in PSP, using the PSP Rating Scale (PSPRS) over 52 weeks. The trial also...

    1 comment
  • Recruiting participants for a groundbreaking study: “Assessing Cognitive Trajectories in Progressive Supranuclear Palsy Using Remote Computerized Reaction Time Tasks.”

    Recruiting participants for a groundbreaking st...

    Melbourne, Victoria – September 9, 2025 – The CCF Coleen Cunningham Foundation is partnering with researchers at the Alfred Hospital and Monash University to recruit participants for a groundbreaking study:...

    Recruiting participants for a groundbreaking st...

    Melbourne, Victoria – September 9, 2025 – The CCF Coleen Cunningham Foundation is partnering with researchers at the Alfred Hospital and Monash University to recruit participants for a groundbreaking study:...

1 of 4